BioSenic

Organization

Publications in OpenAlex of which a co-author is affiliated to this organization

All publications | By field | By subfield

All publications [Next]
Title DOI
https://doi.org/10.1158/1538-7445.sabcs18-3249 Abstract 3249: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells
https://doi.org/10.1158/1538-7445.sabcs18-3261 Abstract 3261: EOS100850, a non-brain penetrant highly selective A2Areceptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment
https://doi.org/10.1093/annonc/mdz452.010 Multiplex IHC panel development for adenosine pathway markers and TIL in human cancer specimens
https://doi.org/10.1136/annrheumdis-2020-eular.5227 THU0487 DIAGNOSTIC DILEMMA: WHICH CLINICAL TEST IS MOST ACCURATE FOR DIAGNOSING SUPRASPINATUS MUSCLE TEARS AND TENDINOSIS?
https://doi.org/10.1158/1538-7445.am2019-4969 Abstract 4969: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity
https://doi.org/10.1055/s-009-44644
https://doi.org/10.1158/1538-7445.sabcs18-3240 Abstract 3240: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells
https://doi.org/10.1158/1538-7445.am2019-4154 Abstract 4154: EOS100850 inhibits A2A receptor signaling in human whole blood: Two pharmacodynamic assays to monitor EOS100850 activity in clinical studies
https://doi.org/10.1080/21645515.2017.1315265 iTeos Therapeutics
https://doi.org/10.1158/1538-7445.sabcs18-4147 Abstract 4147: EOS100850, an A2Areceptor antagonist with prolonged pharmacodynamic activity, mediates the generation ofspecific durable immune responses in a murine breast cancer model
Comparison of HR-MRI with µCT arthrography for the morphological assessment of non-human primate models of osteoarthritis
https://doi.org/10.18063/jmds.v1i2.135 Cell therapy for bone fracture repair: A comparative preclinical review of mesenchymal stromal cells from bone marrow and from adipose tissue
https://doi.org/10.1101/2023.04.19.536389 THE OLFACTORY RECEPTOR Olfr78 REGULATES DIFFERENTIATION OF ENTEROCHROMAFFIN CELLS IN THE MOUSE COLON
https://doi.org/10.21203/rs.3.rs-3231021/v1 Cannabidiol ameliorates mitochondrial disease via PPARγ activation
https://doi.org/10.1158/1538-7445.am2024-3233 Abstract 3233: EP102: Pharmacological Inhibition of METTL3 causes tumor growth inhibition and prolongs survival in preclinical models of NSCLC, ovarian and squamous cell carcinoma
https://doi.org/10.1016/j.esmoop.2024.102686 107TiP Dry powder inhaled cisplatin in stage IV NSCLC: The phase I/IIa CIS-DPI-01 study
https://doi.org/10.1016/j.toxicon.2024.107951 Identification of potential anticancer peptides from animal venoms using mass spectrometry techniques
https://doi.org/10.1136/jitc-2024-sitc2024.1033 1033 An Arenavirus-based immunotherapy designed to target a wide range of tumors expressing cancer testis antigens PRAME and MAGE-As
https://doi.org/10.1016/j.iotech.2024.100971 218P A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
https://doi.org/10.1016/j.iotech.2024.100751 122P Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
https://doi.org/10.1016/j.iotech.2024.101008 48P The A2AR antagonist inupadenant promotes humoral responses in preclinical models
https://doi.org/10.1016/j.iotech.2024.100927 174MO The A2AR antagonist inupadenant promotes humoral responses in patients
https://doi.org/10.1016/j.iotech.2024.100749 120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial
https://doi.org/10.1016/j.pep.2025.106660 Expression and purification of an activated orexin receptor 1- G-protein complex
https://doi.org/10.1158/1538-7445.am2025-5714 Abstract 5714: EP102: pharmacological inhibition of METTL3 in tumor growth inhibition and comparative efficacy in combination with anti-PD1 or PARP inhibitors
https://doi.org/10.1158/1538-7445.am2025-4277 Abstract 4277: EP601: Agonism of GPR84 activates myeloid cells and augments the response to anti-CTLA4 to promote tumor growth inhibition and prolong survival in a syngeneic (CT26) tumor model
https://doi.org/10.1158/1538-7445.am2025-5609 Abstract 5609: A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response
https://doi.org/10.1101/2025.08.13.669666 A2AR-mediated inhibition of B cell maturation: a novel mechanism of immune suppression in cancer
https://doi.org/10.3390/vaccines13080865 Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification
https://doi.org/10.1016/j.toxlet.2025.07.237 P05-04 Protective effects of anethol trithione against cardiac toxicity induced by doxorubicin through a mitochondrial interaction
https://doi.org/10.1093/nar/gkaf1171 Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response
https://doi.org/10.1016/j.toxicon.2025.108927 Patentability of natural products from Venomous Organisms: A guide for life science researchers
https://doi.org/10.1016/j.biopha.2025.118848 ENT1 inhibition enhances weight control and metabolic health in diet-induced obesity
https://doi.org/10.3389/fimmu.2025.1702402 Inhibition of A2AR alleviates adenosine-mediated suppression of plasma cell differentiation
Inorganic-organic Composite Bone Scaffolds for Optimizing Bone Regeneration
https://doi.org/10.1158/1538-7445.am2026-7062 Abstract 7062: EP102: Pharmacological inhibition of METTL3 is effective as a monotherapy and potentiates radiation therapy in pancreatic adenocarcinoma via DNA damage and stemness modulation.